Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Feasibility and acute toxicity of Concurrent Chemoradiotherapy (CCRT) with high-dose rate intracavitary brachytherapy (HDR-ICBT) and 40-mg/m2 weekly cisplatin for Japanese patients with cervical cancer: results of a Multi-Institutional Phase 2 Study (JGOG1066).

Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K; Cervical Cancer Vulva Cancer Committee of the Japanese Gynecologic Oncology Group.

Int J Gynecol Cancer. 2012 Oct;22(8):1420-6.

PMID:
22932262
2.

Phase II study of concurrent chemoradiotherapy with high-dose-rate intracavitary brachytherapy in patients with locally advanced uterine cervical cancer: efficacy and toxicity of a low cumulative radiation dose schedule.

Toita T, Kitagawa R, Hamano T, Umayahara K, Hirashima Y, Aoki Y, Oguchi M, Mikami M, Takizawa K; Cervical Cancer (Vulva Cancer) Committee of Japanese Gynecologic Oncology Group (JGOG).

Gynecol Oncol. 2012 Aug;126(2):211-6. doi: 10.1016/j.ygyno.2012.04.036. Epub 2012 Apr 30.

PMID:
22555110
3.

Radiotherapy quality assurance of the Japanese Gynecologic Oncology Group study (JGOG1066): a cooperative phase II study of concurrent chemoradiotherapy for uterine cervical cancer.

Toita T, Kato S, Ishikura S, Tsujino K, Kodaira T, Uno T, Hatano K, Sakurai H, Niibe Y, Kazumoto T, Nishimura T, Kitagawa R, Fukutani M, Oguchi M, Umayahara K, Hirashima Y, Aoki Y, Takizawa K; Disease Committee of Radiation Oncology, Japanese Gynecologic Oncology Group.

Int J Clin Oncol. 2011 Aug;16(4):379-86. doi: 10.1007/s10147-011-0196-4. Epub 2011 Feb 18.

PMID:
21331768

Supplemental Content

Loading ...
Support Center